The global Non-prescription Drugs market size was valued at US$ 122430 million in 2023. With growing demand in downstream market, the Non-prescription Drugs is forecast to a readjusted size of US$ 180540 million by 2030 with a CAGR of 5.7% during review period.
The research report highlights the growth potential of the global Non-prescription Drugs market. Non-prescription Drugs are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Non-prescription Drugs. 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Non-prescription Drugs market.
A听medication听(also referred to as听medicine,听pharmaceutical drug, or simply听drug) is a听drug听used to听diagnose,听cure,听treat, or听prevent听disease.听Drug therapy (pharmacotherapy) is an important part of the听medical field听and relies on the science of听pharmacology听for continual advancement and on听pharmacy听for appropriate management.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Non-prescription Drugs market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the Non-prescription Drugs market. It may include historical data, market segmentation by Type (e.g., Brand Drugs, Generic Drug), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Non-prescription Drugs market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Non-prescription Drugs market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Non-prescription Drugs industry. This include advancements in Non-prescription Drugs technology, Non-prescription Drugs new entrants, Non-prescription Drugs new investment, and other innovations that are shaping the future of Non-prescription Drugs.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Non-prescription Drugs market. It includes factors influencing customer ' purchasing decisions, preferences for Non-prescription Drugs product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Non-prescription Drugs market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Non-prescription Drugs market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Non-prescription Drugs market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Non-prescription Drugs industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Non-prescription Drugs market.
麻豆原创 Segmentation:
Non-prescription Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Brand Drugs
Generic Drug
Segmentation by application
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Roche
Sanofi
Johnson & Johnson
Merck & Co. (MSD)
Novartis
AbbVie
Gilead Sciences
GlaxoSmithKline (GSK)
Amgen
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
Teva
Bayer
Novo Nordisk
AbbVie
Takeda
Boehringer Ingelheim
Takeda
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Non-prescription Drugs 麻豆原创 Size 2019-2030
2.1.2 Non-prescription Drugs 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Non-prescription Drugs Segment by Type
2.2.1 Brand Drugs
2.2.2 Generic Drug
2.3 Non-prescription Drugs 麻豆原创 Size by Type
2.3.1 Non-prescription Drugs 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Non-prescription Drugs 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Non-prescription Drugs Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Non-prescription Drugs 麻豆原创 Size by Application
2.5.1 Non-prescription Drugs 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Non-prescription Drugs 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Non-prescription Drugs 麻豆原创 Size by Player
3.1 Non-prescription Drugs 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global Non-prescription Drugs Revenue by Players (2019-2024)
3.1.2 Global Non-prescription Drugs Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Non-prescription Drugs Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Non-prescription Drugs by Regions
4.1 Non-prescription Drugs 麻豆原创 Size by Regions (2019-2024)
4.2 Americas Non-prescription Drugs 麻豆原创 Size Growth (2019-2024)
4.3 APAC Non-prescription Drugs 麻豆原创 Size Growth (2019-2024)
4.4 Europe Non-prescription Drugs 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa Non-prescription Drugs 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Non-prescription Drugs 麻豆原创 Size by Country (2019-2024)
5.2 Americas Non-prescription Drugs 麻豆原创 Size by Type (2019-2024)
5.3 Americas Non-prescription Drugs 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Non-prescription Drugs 麻豆原创 Size by Region (2019-2024)
6.2 APAC Non-prescription Drugs 麻豆原创 Size by Type (2019-2024)
6.3 APAC Non-prescription Drugs 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Non-prescription Drugs by Country (2019-2024)
7.2 Europe Non-prescription Drugs 麻豆原创 Size by Type (2019-2024)
7.3 Europe Non-prescription Drugs 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Non-prescription Drugs by Region (2019-2024)
8.2 Middle East & Africa Non-prescription Drugs 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Non-prescription Drugs 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Non-prescription Drugs 麻豆原创 Forecast
10.1 Global Non-prescription Drugs Forecast by Regions (2025-2030)
10.1.1 Global Non-prescription Drugs Forecast by Regions (2025-2030)
10.1.2 Americas Non-prescription Drugs Forecast
10.1.3 APAC Non-prescription Drugs Forecast
10.1.4 Europe Non-prescription Drugs Forecast
10.1.5 Middle East & Africa Non-prescription Drugs Forecast
10.2 Americas Non-prescription Drugs Forecast by Country (2025-2030)
10.2.1 United States Non-prescription Drugs 麻豆原创 Forecast
10.2.2 Canada Non-prescription Drugs 麻豆原创 Forecast
10.2.3 Mexico Non-prescription Drugs 麻豆原创 Forecast
10.2.4 Brazil Non-prescription Drugs 麻豆原创 Forecast
10.3 APAC Non-prescription Drugs Forecast by Region (2025-2030)
10.3.1 China Non-prescription Drugs 麻豆原创 Forecast
10.3.2 Japan Non-prescription Drugs 麻豆原创 Forecast
10.3.3 Korea Non-prescription Drugs 麻豆原创 Forecast
10.3.4 Southeast Asia Non-prescription Drugs 麻豆原创 Forecast
10.3.5 India Non-prescription Drugs 麻豆原创 Forecast
10.3.6 Australia Non-prescription Drugs 麻豆原创 Forecast
10.4 Europe Non-prescription Drugs Forecast by Country (2025-2030)
10.4.1 Germany Non-prescription Drugs 麻豆原创 Forecast
10.4.2 France Non-prescription Drugs 麻豆原创 Forecast
10.4.3 UK Non-prescription Drugs 麻豆原创 Forecast
10.4.4 Italy Non-prescription Drugs 麻豆原创 Forecast
10.4.5 Russia Non-prescription Drugs 麻豆原创 Forecast
10.5 Middle East & Africa Non-prescription Drugs Forecast by Region (2025-2030)
10.5.1 Egypt Non-prescription Drugs 麻豆原创 Forecast
10.5.2 South Africa Non-prescription Drugs 麻豆原创 Forecast
10.5.3 Israel Non-prescription Drugs 麻豆原创 Forecast
10.5.4 Turkey Non-prescription Drugs 麻豆原创 Forecast
10.5.5 GCC Countries Non-prescription Drugs 麻豆原创 Forecast
10.6 Global Non-prescription Drugs Forecast by Type (2025-2030)
10.7 Global Non-prescription Drugs Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 Pfizer
11.1.1 Pfizer Company Information
11.1.2 Pfizer Non-prescription Drugs Product Offered
11.1.3 Pfizer Non-prescription Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Pfizer Main Business Overview
11.1.5 Pfizer Latest Developments
11.2 Roche
11.2.1 Roche Company Information
11.2.2 Roche Non-prescription Drugs Product Offered
11.2.3 Roche Non-prescription Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Roche Main Business Overview
11.2.5 Roche Latest Developments
11.3 Sanofi
11.3.1 Sanofi Company Information
11.3.2 Sanofi Non-prescription Drugs Product Offered
11.3.3 Sanofi Non-prescription Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Sanofi Main Business Overview
11.3.5 Sanofi Latest Developments
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Information
11.4.2 Johnson & Johnson Non-prescription Drugs Product Offered
11.4.3 Johnson & Johnson Non-prescription Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Johnson & Johnson Main Business Overview
11.4.5 Johnson & Johnson Latest Developments
11.5 Merck & Co. (MSD)
11.5.1 Merck & Co. (MSD) Company Information
11.5.2 Merck & Co. (MSD) Non-prescription Drugs Product Offered
11.5.3 Merck & Co. (MSD) Non-prescription Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Merck & Co. (MSD) Main Business Overview
11.5.5 Merck & Co. (MSD) Latest Developments
11.6 Novartis
11.6.1 Novartis Company Information
11.6.2 Novartis Non-prescription Drugs Product Offered
11.6.3 Novartis Non-prescription Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Novartis Main Business Overview
11.6.5 Novartis Latest Developments
11.7 AbbVie
11.7.1 AbbVie Company Information
11.7.2 AbbVie Non-prescription Drugs Product Offered
11.7.3 AbbVie Non-prescription Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 AbbVie Main Business Overview
11.7.5 AbbVie Latest Developments
11.8 Gilead Sciences
11.8.1 Gilead Sciences Company Information
11.8.2 Gilead Sciences Non-prescription Drugs Product Offered
11.8.3 Gilead Sciences Non-prescription Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Gilead Sciences Main Business Overview
11.8.5 Gilead Sciences Latest Developments
11.9 GlaxoSmithKline (GSK)
11.9.1 GlaxoSmithKline (GSK) Company Information
11.9.2 GlaxoSmithKline (GSK) Non-prescription Drugs Product Offered
11.9.3 GlaxoSmithKline (GSK) Non-prescription Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 GlaxoSmithKline (GSK) Main Business Overview
11.9.5 GlaxoSmithKline (GSK) Latest Developments
11.10 Amgen
11.10.1 Amgen Company Information
11.10.2 Amgen Non-prescription Drugs Product Offered
11.10.3 Amgen Non-prescription Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Amgen Main Business Overview
11.10.5 Amgen Latest Developments
11.11 AstraZeneca
11.11.1 AstraZeneca Company Information
11.11.2 AstraZeneca Non-prescription Drugs Product Offered
11.11.3 AstraZeneca Non-prescription Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 AstraZeneca Main Business Overview
11.11.5 AstraZeneca Latest Developments
11.12 Bristol-Myers Squibb
11.12.1 Bristol-Myers Squibb Company Information
11.12.2 Bristol-Myers Squibb Non-prescription Drugs Product Offered
11.12.3 Bristol-Myers Squibb Non-prescription Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.12.4 Bristol-Myers Squibb Main Business Overview
11.12.5 Bristol-Myers Squibb Latest Developments
11.13 Eli Lilly
11.13.1 Eli Lilly Company Information
11.13.2 Eli Lilly Non-prescription Drugs Product Offered
11.13.3 Eli Lilly Non-prescription Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.13.4 Eli Lilly Main Business Overview
11.13.5 Eli Lilly Latest Developments
11.14 Teva
11.14.1 Teva Company Information
11.14.2 Teva Non-prescription Drugs Product Offered
11.14.3 Teva Non-prescription Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.14.4 Teva Main Business Overview
11.14.5 Teva Latest Developments
11.15 Bayer
11.15.1 Bayer Company Information
11.15.2 Bayer Non-prescription Drugs Product Offered
11.15.3 Bayer Non-prescription Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.15.4 Bayer Main Business Overview
11.15.5 Bayer Latest Developments
11.16 Novo Nordisk
11.16.1 Novo Nordisk Company Information
11.16.2 Novo Nordisk Non-prescription Drugs Product Offered
11.16.3 Novo Nordisk Non-prescription Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.16.4 Novo Nordisk Main Business Overview
11.16.5 Novo Nordisk Latest Developments
11.17 AbbVie
11.17.1 AbbVie Company Information
11.17.2 AbbVie Non-prescription Drugs Product Offered
11.17.3 AbbVie Non-prescription Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.17.4 AbbVie Main Business Overview
11.17.5 AbbVie Latest Developments
11.18 Takeda
11.18.1 Takeda Company Information
11.18.2 Takeda Non-prescription Drugs Product Offered
11.18.3 Takeda Non-prescription Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.18.4 Takeda Main Business Overview
11.18.5 Takeda Latest Developments
11.19 Boehringer Ingelheim
11.19.1 Boehringer Ingelheim Company Information
11.19.2 Boehringer Ingelheim Non-prescription Drugs Product Offered
11.19.3 Boehringer Ingelheim Non-prescription Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.19.4 Boehringer Ingelheim Main Business Overview
11.19.5 Boehringer Ingelheim Latest Developments
11.20 Takeda
11.20.1 Takeda Company Information
11.20.2 Takeda Non-prescription Drugs Product Offered
11.20.3 Takeda Non-prescription Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.20.4 Takeda Main Business Overview
11.20.5 Takeda Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
